



## SPECIFICATION

With respect to Office Action paragraph 1, the specification has been amended on page 11, lines 10-12, to delete [which has the amino acid sequence LIRX<sub>1</sub>NN X<sub>2</sub>T X<sub>3</sub> X<sub>4</sub> X<sub>3</sub> X<sub>1</sub> X<sub>1</sub>, where X<sub>1</sub> is any amino acid; X<sub>2</sub> is any amino acid, but not L or R; X<sub>3</sub> is a charged amino acid; and, when present, X<sub>4</sub> is a charged amino acid], in order to remove reference to an algorithm or consensus sequence, as previously agreed.

## CLAIM OBJECTIONS

With respect to Office Action paragraph 1, Claim 4 is an independent claim defining a pharmaceutical composition consisting of the peptides recited in claim 3 and a pharmaceutically acceptable carrier. It is not a dependent claim.

## CONCLUSION

In summary, for the reasons set forth herein, Applicant maintains that claims 3 - 8, as now amended, clearly and patentably define the invention by removing any reference to the contentious algorithm (generic consensus sequence) as previously agreed. Therefore, Applicant respectfully requests that the Examiner reconsider the various grounds set forth in the Office Action, and allow the claims now pending.

If the Examiner would like to discuss any of the issues raised in the Office Action, Applicants' representative can be reached at (760) 788-7401.

Respectfully submitted,

Date: 05/14/01

William C. Fuess  
William C. Fuess

FUESS & DAVIDENAS  
10951 Sorrento Valley Rd., Ste. II-G  
San Diego, CA 92121  
Telephone: (760) 788-7401  
Facsimile: (760) 788-5846